| 前收市價 | 0.75 |
| 開市 | 0.75 |
| 買盤 | 5.70 |
| 賣出價 | 8.15 |
| 拍板 | 19.50 |
| 到期日 | 2024-06-28 |
| 今日波幅 | 0.44 - 8.53 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 162 |
Barrons.comCassava Sciences Shares Plunge on Indictment Against Former Advisor
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
ZacksCassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
InvestorPlaceStock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
Investing in the biotech sphere isn’t for the faint of heart, and you should steer clear of the biotech stocks to avoid. That’s because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals. Unsurprisingly, the SPDR S&P Biotech ETF had shed roughly 40% in value over the past three years, when the broader market gained 22%. Hence, investors pondering over biotech stocks to avoid them will always remain relevant. Moreover, they’re probably
